BC Advantage Funds
VC Fund
North Vancouver, Canada
BC Advantage Funds is a venture capital firm that caters to early stage life science, technology, and clean tech companies.In 2006, the company received the Canadian Venture Capital Association 'Deal of the Year' award for achieving the highest realized return on a single investment (23.4X return on our investment in AsprevaPharmaceuticals) of any venture capital firm in Canada. Furthermore, in the three years prior to its redemption (2006,2007, 2008), its Advantage Life Science Fund I provided the highest 5-year returns of any retail fund in Canada (Source: GlobeFund). Advantage most recent venture capital fund, the Advantage Structured Fund, was primarily raised and invested in the robust pre financial-crisis environment of 2004 – 2007. Since the financial crisis and recession of 2008 – 2009, we have had the challenging task of growing these businesses, keeping them financed despite difficult capital markets, and seeking profitable exits from the investments in a post financial-crisis environment characterized by few (if any) initial public offerings (IPOs), depressed activity in merger and acquisition (M&A) markets, and weakened valuations for emerging technology companies.In July, 2016, Advantage announced that its Board of Directors had concluded a review of strategic alternatives and determined that a liquidation and dissolution of the Company is the best alternative for maximizing shareholder value. The Board subsequently called an annual and special meeting of shareholders of the Company to approve a number of items, including the voluntary dissolution of the Company under Division 2 of Part 10 of the Business Corporations Act (British Columbia), the settlement of all of the assets of the Company on the Liquidation Trustee (as defined in the information circular in respect of the Meeting) on trust that the Trustee assume and pay all of the liabilities of the Company, and distribute all remaining assets of the Trust rateably to the shareholders of record. The Dissolution Resolution was approved by way of an ordinary and special resolution passed by a majority and at least two-thirds, respectively, of the votes cast by the Company’s shareholders the Meeting.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries BC Advantage Funds invests in
Stages BC Advantage Funds invests in
Countries BC Advantage Funds invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ambrose Hong
|
|||
Avtar Dhillon
|
|||
Bob Rieder
|
|||
Don Rix
|
|||
Frank Holler
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- CRM 1 (20%)
- Finance 1 (20%)
- Medical 1 (20%)
Stage
- Series B 2 (40%)
- Funding Round 2 (40%)
- Series A 1 (20%)
Country
- Canada 3 (60%)
- United Kingdom 2 (40%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ambrose Hong
CFO
|
CFO | Total investments: 0 | Find email | |
|
Avtar Dhillon
Director
|
Director | Total investments: 0 | Find email | |
|
Bob Rieder
Director
|
Director | Total investments: 0 | Find email | |
|
Don Rix
Chairman
|
Chairman | Total investments: 0 | Find email | |
|
Frank Holler
CEO and Partner
|
CEO and Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Microvisk Technologies
|
Microvisk Technologies is a UK based company developing Micro Electro Mechanical Sensors for the international medical market. | $2.6M / Jan 28, 2010 | |
Inimex Pharmaceuticals
|
Inimex Pharmaceuticals, Inc. is a clinical stage company focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body's innate defenses without causing inflammation. | $22M / Series B / Jun 02, 2008 | |
NPS
|
NPS was founded in November 2003 in order to exploit polymer technology invented and developed by UK Government research laboratories. Having established an exclusive licence to the technology, NPS has been working to apply it to specific applications across many industries. | $9.7M / May 16, 2008 | |
Aquinox Pharmaceuticals
|
Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program forblood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada. | $14.5M / Series A / Jun 12, 2007 | |
GaleForce Solutions
|
GaleForce Solutions Inc. designs and delivers customer relations management (CRM) solutions for the financial services industry in Canada and internationally. Its solutions include GaleForce CRM for Financial Services, an enterprise module to the daily workflow of client-facing personnel; GaleForce CRM for Banking, a CRM solution for theclient-facing staff of commercial banks, retail banks, and credit unions; GaleForce CRM for Wealth Management, a CRM solution to financial advisors, and account and portfolio managers; and GaleForce CRM for Investment Banking, a CRM solution to investment bankers and support staff. The company's solutions also include GaleForce CRM for Capital Markets, a CRM solution to securities broker dealers, bond and mutual fund brokers and dealers, and research and investment professionals in the capital markets; GaleForce Solutions Data Importer, an user interface that allows users to import data; and GaleForce Online CRM, an online hosted CRM solution for financial services. In addition, it offers maintenance, support, and consultation services; and training courses. The company serves wealth management and multi-family office, retail, commercial and investment banking, and capital markets firms. It provides its solutions through a network of system integration and reseller partners. GaleForce Solutions, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. | $2.1M / Series B / Apr 25, 2006 |
Co-Investors
Discovery Capital
2 deals together
Astellas Venture Management
1 deal together
Baker Brothers Advisors LLC
1 deal together
BDC Venture Capital
1 deal together
Canadian Medical Discoveries Fund
1 deal together
Development Bank of Wales
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does BC Advantage Funds invest in?
BC Advantage Funds invests primarily in Health Care, Biotechnology and CRM startups, most often at Series B and Funding Round stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BC Advantage Funds?
Public channels for BC Advantage Funds include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BC Advantage Funds?
The team at BC Advantage Funds includes Ambrose Hong (CFO), Avtar Dhillon (Director) and Bob Rieder (Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
